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Inflammatory bowel diseases (IBD) are characterized by chronic inflammation of the intestinal tract associated with an imbalance
of the intestinal microbiota. Crohn’s disease (CD) and ulcerative colitis (UC) are themost widely known types of IBD and have been
the focus of attention due to their increasing incidence. Recent studies have pointed out genes associated with IBD susceptibility
that, together with environment factors, may contribute to the outcome of the disease. In ulcerative colitis, there are several
therapies available, depending on the stage of the disease. Aminosalicylates, corticosteroids, and cyclosporine are used to treat
mild, moderate, and severe disease, respectively. In Crohn’s disease, drug choices are dependent on both location and behavior of
the disease. Nowadays, advances in treatments for IBD have included biological therapies, based mainly on monoclonal antibodies
or fusion proteins, such as anti-TNF drugs. Notwithstanding the high cost involved, these biological therapies show a high index
of remission, enabling a significant reduction in cases of surgery and hospitalization. Furthermore, migration inhibitors and new
cytokine blockers are also a promising alternative for treating patients with IBD. In this review, an analysis of literature data on
biological treatments for IBD is approached, with the main focus on therapies based on emerging recombinant biomolecules.
1. Introduction
The role of intestinal milieu in immune homeostasis appears
to be of greater significance than it was previously thought.
This complex interplay of genetic, microbial, and environ-
mental factors culminates in a sustained activation of the
mucosal immune and nonimmune responses. Under normal
situations, the intestinal mucosa is in a state of “controlled”
inflammation regulated by a delicate balance of Th1, Th17,
Th2, Th3, Th9, and Treg cells [1–6].
Inflammatory bowel diseases (IBD) are related to an
immunological imbalance of the intestinal mucosa, mainly
associated with cells of the adaptive immune system, which
respond against self-antigens producing chronic inflamma-
tory conditions in these patients. Ulcerative colitis (UC)
and Crohn’s disease (CD) are the most studied types of
inflammatory bowel diseases, having the highest prevalence
in the world population.The pathophysiological mechanisms
of IBD are not fully understood, although these diseases have
been discovered several decades ago [7–10]. In the present
work, we aim to review the current approaches for treating
IBD, focusing on the new therapies based on biological
molecules.
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2. Inflammatory Bowel Disease
It is widely known that the number of bacteria in the
gastrointestinal tract is about 10 times higher when compared
to eukaryotic cells in the body. Also, the normal enteric
bacterial flora is a complex ecosystem of approximately 300–
500 bacterial species [11, 12]. Moreover, the balance of the
innate and adaptive immunity is critical for this microen-
vironment homeostasis. In this sense, the immune system
has the important role of promoting immune tolerance,
thereby avoiding the specific immune response against the
large mass of commensal bacteria. The local immunity in
intestinal mucosa is basically ensured by gut associated
lymphoid tissue (GALT), constituted by Peyer’s patches,
lymphoid follicles, and mesenteric lymph nodes [13]. Along
with cellular, environmental, and genetic factors, deregu-
lation of immune responses in the intestinal mucosa has
been associated with the etiology of IBD. Alterations in the
autophagy—a cellular process related to the degradation of
intracellular pathogens, antigen processing, regulation of cell
signaling and T cell homeostasis—usually results in reduced
clearance of pathogens, thus contributing to the onset of
inflammatory disorders in susceptible subjects [14, 15]. In this
sense, mutations on ATG16L1 gene, a member of a family of
genes involved in autophagy, were detected in patients with
CD [16].
The breakage of self-antigens tolerance in the intestinal
mucosa, by injury or genetic predisposition, may lead to
CD or UC [17, 18]. Cells of the innate immunity, such as
macrophages and dendritic cells, are specialized in identify-
ing microorganism’s molecular patterns by using the pattern
recognition receptors (PRR), such as toll-like receptors (TLR)
and nucleotide-binding oligomerization domains (NOD). In
this regard, mutations in the caspase recruitment domain-
containing protein 15 (CARD-15) gene encoding the NOD-2
proteinwere associatedwith the occurrence of IBD, especially
CD. NOD2 is an intracellular microbial sensor that acts as
a potent activator and regulator of inflammation. Therefore,
deficiency in this protein promotes important changes on
the immune response in the lamina propria, producing a
chronic inflammation in the tissue. Clinically, it is of interest
to determine the relationship between NOD2 gene status and
the efficacy of antibiotic treatment in CD [19–22].
Likewise, the imbalance between Th1 and Th2 cytokines
released by the intestinal mucosa determines the intensity
and duration of the inflammatory response in experimental
colitis [23]. The secretion of certain cytokines such as tumor
necrosis factor-alpha (TNF-𝛼) [24, 25], transforming growth
factor-beta (TGF-𝛽) [23, 26, 27], and interferon-gamma
(IFN-𝛾) [28, 29] as well as the response to self-antigens [30–
32] are factors that seem to be related to the onset and
establishment of IBD.AlthoughUC is often described asTh2-
mediated diseases while CD is known as aTh1 condition, the
classic paradigm has recently been changed, since cytokines
can have diverse and opposing actions [33].
Recent data showed that Th17 cells and other cells
producing interleukin- (IL-) 17 play a crucial role in the
intestinal inflammatory manifestations. IL-17 and IL-22
appear to be related to the induction of colitis, since these
cytokines initiate and amplify the local inflammatory signs
and promote the activation of counter-regulatory mecha-
nisms targeting intestinal epithelium cells [34]. Also IL-23,
released by macrophages and dendritic cells located in the
intestinal mucosa, activates signal transducer and activator
of transcription- (STAT-) 4 in memory T lymphocytes,
stimulating the production of IFN-𝛾. In turn, IFN-𝛾 is
responsible for triggering the production of inflammatory
cytokines in cells of the innate immune system, contributing
to the increase of the inflammation present in colitis [35].
Latest results from Neurath group [3] identified a pathogenic
role of IL-9 in experimental and human ulcerative colitis by
regulating intestinal epithelial cells.
It is also important to report that environmental factors
can play a significant role in the development of IBD,
although this relationship is poorly understood. Particularly,
there are several evidences that tobacco could have an impor-
tant role in triggering this type of intestinal inflammation
[36, 37].
2.1. Crohn’s Disease. Crohn’s disease, one of themost frequent
forms of inflammatory disease worldwide, is characterized
by the formation of strictures, fistulas, ulcers, and granu-
lomas in the mucosa. Although the CD’s gastrointestinal
manifestation can primarily affect the terminal ileum region,
it can also compromise any region from the mouth to the
rectum of affected patient. The clinical manifestations of
CD can include diarrhea or bloody diarrhea, malnutrition,
abdominal pain, and weight loss. Extraintestinal findings, for
instance, arthropathy or skin disorders, rarely occur. How-
ever, manifestations on skin, muscle, or bone of metastatic
Crohn’s disease can actually lead to recognition of occult
intestinal disease [80–82]. In general, CD has a genetic back-
ground and the first-degree relatives of affected individuals
have a fivefold greater risk of developing the disease [83, 84].
The localized release of certain cytokines, such as IL-12,
IL-17, TNF-𝛼, and IFN-𝛾, has been implicated in the chronic
intestinal inflammation observed in CD patients [51, 85].The
production of IL-12 and IL-18 by antigen-presenting cells
(APC) andmacrophages generates a polarized differentiation
towards Th1 lymphocyte, leading to an increased release of
proinflammatory cytokines, including TNF-𝛼 and IFN-𝛾.
Additionally, Th1 cytokines stimulate the antigen-presenting
cells to secrete a wider spectrum of inflammatory cytokines
such as IL-1, IL-6, IL-8, IL-12, and IL-18, resulting in a self-
sustained cycle [86].
2.2. Ulcerative Colitis. Ulcerative colitis is another form of
IBD characterized by superficial ulcerations, granularity, and
a vascular pattern. In contrast with the inflammation found
in CD—transmural and being able to occur throughout the
entire gastrointestinal tract—inflammation in UC is limited
to the mucosal layer of the colon [87, 88]. AlthoughMontreal
classification—a system to classify IBD phenotypes including
UC—is widely used, data on its reliability are very limited due
to the great variety of clinical presentations of UC [88]. In
general, the clinical manifestation of UC can include release
of blood and mucus, petechial hemorrhage, and granulation
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tissue, among others. However, in periods of remission, the
mucosa may have normal appearance. In most severe forms
of the disease, the intestine can get distended, presenting deep
ulceration and possibly intestinal perforation [87, 89].
In UC, there is a substantial increase in the secretion
of IL-13, the main interleukin responsible for the inflamma-
tion and chronicity of this condition [87]. Despite the Th1
involvement, UC patients also present a Th2 response with
increased secretion of IL-4, IL-5, and IL-9 [3, 5]. It has been
suggested that the expression of the PU.1 transcription factor,
a regulator of cellular communication, and the production
of IL-9 by effectors’ Th9 cells block the proliferation of
intestinal epithelial cells and regulate the expression of several
tight-junction proteins. Together, these aspects favor the
translocation of specific bacterial species with subsequent
activation of immune cells and mucosal inflammation in
experimental and human UC [3]. As in CD, Th17-related
cytokines are also increased in UC [34, 90].
3. Treatments for IBD
In order to better illustrate the relevance of each of the
different IBD treatments, Table 1 compares different forms
of treatment, mechanisms of action, patterns, and adverse
effects of each form of therapy.
3.1. Classical Treatments for IBD. In ulcerative colitis, treat-
ment decision is dependent on the stage of the disease:
patients with mild manifestations are usually treated with
aminosalicylates, whereas corticosteroids are prescribed for
those with moderate disease and cyclosporine is given to
patients with severe disease. In Crohn’s disease, decisions
about drug therapy are dependent on both location and
behavior of the disease. Despite that, the medication in
CD usually includes aminosalicylates and antibiotics to treat
mild mucosal disease, corticosteroids to moderate disease,
and biological molecules to treat fistulizing disease. Also,
aminosalicylates, azathioprine, mercaptopurine, methotrex-
ate, metronidazole, and associations can be used as mainte-
nance therapies [38, 39, 42, 80, 91–94]. Notwithstanding their
reduced cost, these drugs can generate several side effects.
Moreover, these therapies do not achieve clinical remission
and they can lead to the onset of other conditions such as
renal impairment [39, 49, 50].
At the same time the classical treatments are widely
used, new therapies are under development in the attempt
of improving the patient’s life quality. The new therapies aim
to reduce the side effects and to treat patients who do not
respond satisfactorily to conventional therapies [51, 52, 74, 95,
96].
Other therapeutic strategies, not covered in this review,
are in very early evaluation.These involve themanipulation of
the microbiome using antibiotics, probiotics, prebiotics, diet,
and fecal microbiota transplantation [93, 97, 98].
3.2. Biological Therapies. The application of biological ther-
apy for the treatment of inflammatory diseases can be associ-
ated with some studies that identified the proinflammatory
cytokines present in the gut lamina propria of the IBD
patients. These cytokines, in particular TNF-𝛼, play a crucial
role in the maintenance of chronic inflammation of the
intestinal mucosa [53, 54]. Among the biological molecules,
the use of monoclonal antibodies specific against TNF-𝛼,
cytokine related to the establishment of IBD, seems to be a
relevant alternative. These antibodies may activate various
mechanisms involved in the immune response, such as
induction of apoptosis as well as the blockage of growth
factors for theThcells, antibody production, and complement
activation [99].
Although the treatment of IBDwith biological molecules,
specifically with monoclonal antibodies, presents high speci-
ficity and directed mechanism of action, the high cost of
this therapy still represents a barrier to be overcome. For
this reason, together with this being a therapy in early
stages of development, these drugs are generally used as an
alternative for patients that are refractory to corticosteroid
and aminosalicylates treatments [55, 100].
Also, long-term therapy with biological molecules can
cause immunogenicity by generating anti-drug antibodies.
These antibodies can promote acute and delayed infusion
reactions and can reduce the duration of the patient response
to each infusion or injection [101, 102]. In this sense, there is
a potential contribution of the complement system as well as
of the formation of immune complexes in the augmentation
of immunogenicity [103, 104]. In some patients, immuno-
genicity is restricted to transient low level of antibodies,
presenting no clinical effects. However, patients with high
levels of anti-drug antibodies are more likely to present a loss
of response by the reduction of drug levels, compromising the
long-term therapy [101, 102]. As an alternative, concomitant
immunosuppression appears to reduce immunogenicity and
improve therapeutic control, even though it can present an
increased risk for infection and malignancy [105].
Immunogenicity will depend on structure and origin
of biologic agents. Biologicals can be fusion protein or a
chimeric, and a humanized, or fully human antibody [106].
Also, the administration route, dosing schedule, and indi-
vidual characteristics can have a great impact on immuno-
genicity [104, 106]. It is necessary to determine the optimal
treatment regimen in order to minimize the likelihood of
anti-drug antibody formation.
3.2.1. Anticytokine Agents. Currently, some anticytokine
agents have been showing relevant results for the treatment
of IBD. It is already known that antibodies specific for TNF-
𝛼 play an important role in maintaining the remission of
CD, in both severe and moderate forms of the disease. These
molecules were effective in inducing mucosal healing and
clinical remission, reducing the cases of hospitalization and
surgical procedures in affected individuals [52, 56, 57].
The first commercially available anti-TNF molecule was
infliximab (IFX), a chimeric monoclonal IgG1 antibody [52,
56–58] formed by a segment of the native mouse protein
containing the binding site for the TNF-𝛼 and a portion of
human immunoglobulin responsible for the effector function
of the antibody molecule [25, 54, 59]. With the introduction
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Table 1: IBD treatments: drugs in use, mechanisms of action, and side effects.
Treatment type Related drugs Mechanism of action Features Potentials adverse effects References
Aminosalicylates
Mesalamine
Olsalazine
Balsalazide
Sulfasalazine
Inhibition of IL-1,
TNF-𝛼, and platelet
activating factor
(PAF), decreased
antibody secretion.
Locally
immunosuppressive,
nonspecific inhibition
of cytokines; medium
cost.
Headache, dizziness,
dyspepsia, epigastric pain,
abdominal pain, nausea,
vomiting, and diarrhea.
[38–41]
Immunomodulators
Azathioprin
6-mercaptopurin
Methotrexate
Blockage of de novo
pathway of purine
synthesis.
Antiproliferative
effects, reduction of
inflammation.
Black, tarry stools, bleeding
gums, chest pain, fever,
chills, swollen glands, pain,
cough, and weakness.
[42–48]
Corticosteroids
Prednisone
Methylpred-
nisolone
Hydrocortisone
Budesonide
Blockage of
phospholipase A2 in
the arachidonic acid
cascade altering the
balance between
prostaglandins and
leukotrienes;
stimulation of
apoptosis of lamina
propria lymphocytes;
suppression of the
transcription of
cytokines.
High
immunosuppression,
risk of potential
infections, adverse
effects with long
periods of use, low
cost.
Full moon face, difficulty of
healing, acne, sleep and
mood disturbances, glucose
intolerance, osteoporosis,
osteonecrosis, subcapsular
cataracts, myopathy,
infections, acute adrenal
insufficiency, myalgia,
malaise, arthralgia or
intracranial hypertension,
and pseudorreumatism
syndrome.
[49, 50]
Biologicals: anti-
cytokine drugs
Infliximab
Adalimumab
Certolizumab-
pegol
Golimumab
Ustekinumab
(phase 3 trial)
Induction of
apoptosis in
proinflammatory
cells; binding
specifically to TNF-𝛼,
blockage of the
interaction the
receptor.
Specific inhibition of
cytokine,
immunosuppression,
high cost, advanced
technology required.
Abdominal or stomach
pain, chest pain, chills,
cough, dizziness, fainting,
headache, itching, muscle
pain, nasal congestion,
nausea, sneezing, weakness,
vomiting, bloody urine,
cracks in the skin, diarrhea,
pain, fever, abscess, back or
side pain, bone or joint
pain, constipation, falls,
facial edema, general
feeling of illness, hernia,
irregular heartbeat, unusual
bleeding, weight loss,
increased risk of
reactivation of latent
tuberculosis, and increased
risk for developing
infections and lymphoma.
[24, 51–73]
Biologicals: anti-cell
adhesion molecule
Vedolizumab
Natalizumab
Inhibition of
migration.
Specific inhibition of
cell adhesion
molecules high cost,
advanced technology
required.
Nasopharyngitis, headache
and abdominal pain,
increased risk of infections,
serious infections, and
progressive multifocal
leukoencephalopathy
(natalizumab).
[63, 74–79]
of IFX in market there was a considerable increase of clinical
remission in CD andUC patients. In fact, IFX is currently the
approved biologic agent for the treatment of inflammatory
and fistulizing Crohn’s disease and UC in several countries
[52, 56, 57].
In order to treat nonresponsive patients to IFX, adali-
mumab (ADA), a fully human IgG1 monoclonal antibody,
has emerged as an alternative molecule [58]. ADA is the
first biotechnological product that is produced by using
phage display technology approved by US Food and Drug
Administration (FDA). Administration of ADA is indicated
for individuals with CD in the moderate and severe forms,
also showing positive results for the treatment of UC [58,
60]. The ADA induces apoptosis of proinflammatory cells
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by specifically binding to TNF-𝛼 molecule, leading to the
blockage of the interaction of this cytokine with their surface
receptors p55 and p75 [58].
Biological therapy with monoclonal antibodies IFX and
ADAhas been increasingly employed in the treatment of IBD,
showing a significant improvement of the patient’s clinical
condition. In general, 45–70% of IBD cases presented clinical
remission after being treated with IFX [43, 61, 107], while
patients treated with ADA presented clinical remission near
30–60% [55, 61, 108].
However, the treatment with these molecules involves
several risks and generates side effects. Renal complications,
infusion reaction, delayed hypersensitivity-like reaction, new
onset of autoimmunity (with rare cases of drug-induced lupus
and new-onset demyelination) and opportunistic infections
are some examples of complications resulting from the immu-
nosuppression induced by biological therapy [25, 53, 54, 59,
62]. The fact that these drugs have been recently approved
for clinical practice explains why their side effects are not
thoroughly known. Because of that, more studies should be
conducted in order to fully understand the mechanisms and
the consequences of the use of these drugs. Furthermore,
these anti-TNF agents did not present relevant effects in all
treated patients, indicating another aspect worth investigat-
ing [55, 61, 109–111].
In this context, other anti-TNF biologic agents have
emerged, including CDP 571, etanercept, and onercept.
These humanized or fully human anti-TNF biotechnolog-
ical agents are theoretically less immunogenic than the
chimeric IFX. However, biopharmaceuticals such as etan-
ercept (TNF inhibitor), onercept (recombinant TNF p55
receptor monomer), and CDP571 (recombinant humanized
MAb against TNF-𝛼) were not effective for active Crohn’s
disease [63, 112, 113].
Certolizumab pegol (CDP 870), a pegylated and fully
humanized monoclonal antibody fragment, is an anti-TNF
agent that has recently been approved by FDA for CD treat-
ment with sustained remission [114–116]. Studies show that
this drug seems to be more effective and less immunogenic
than IFX and ADA [63, 64, 117]. Additionally, golimumab,
a human IgG1 TNF-𝛼 antagonist monoclonal antibody,
also showed significant results in inducing and maintaining
remission in CD and UC patients, with a rate of adverse
events similar to the placebo [63, 65, 118].
3.2.2. Leukocyte Migration and Signaling Inhibitors. Since the
application of biological drugs for treating IBD is a novel
approach, there are several new biologic agents that have been
recently approved or included in clinical trials or are under
evaluation for determining their clinical efficacy and safety
profile.
Currently, therapies that manipulate leukocyte adhesion,
costimulatory signaling and cytokine receptors are being
evaluated as potential treatments for IBD. These alternative
treatments emerged when it was observed that some of the
patients under current biologic therapies with anti-TNF-𝛼
agents were primarily nonresponders or experience a loss of
response, intolerance, or even presented side effects [63, 75,
119–122].
Lymphocyte-endothelial interactions, mediated by adhe-
sion molecules, are important in leukocyte migration and
recruitment to sites of inflammation. The selective block-
age of these adhesion molecules is a new and promising
approach to treat CD. Recently approved by FDA, anti-𝛼4
integrinmonoclonal antibodies, specifically natalizumab and
vedolizumab, were effective in the treatment of moderately to
severely active CD (natalizumab and vedolizumab) and for
UC (vedolizumab) patients [10, 63, 123].The blockage of the T
cell migration into the intestine by using anti-𝛼4𝛽7 antibody
vedolizumab, approved to treat adult patients, resulted in a
selective barrier for the trafficking of CD4+CD45RO+T cells.
It also reduced the UC clinical score, presenting a successful
remission in 33% to 50% of cases [74, 76, 124].
Meanwhile, clinical efficacy of some therapeutic agents,
such as inhibitors of leukocyte trafficking, including ali-
caforsen, an oligodeoxynucleotide that inhibits intercellular
adhesion molecule 1 (ICAM-1) expression, are still under
evaluation [123, 125–127]. Among the new drugs being
tested, ustekinumab, a monoclonal antibody against the p40
subunit of interleukin-12/23, approved to use in patients with
moderate or severe psoriasis and psoriatic arthritis, was able
to induce clinical response in patients with moderate-to-
severe CD, especially in those previously treated with IFX
[51, 66]. Etrolizumab, a humanized monoclonal antibody
that selectively binds to the 𝛽7 subunit of the heterodimeric
integrins 𝛼4𝛽7 and 𝛼E𝛽7, was well tolerated in moderate
to severe UC on phase II studies [128, 129]. Additionally,
tofacitinib, a small molecule targeting Janus-activated kinase
(JAK), was shown to particularly inhibit JAK1 and JAK3, also
interfering with several cytokine receptors. However, there
are no relevant clinical data related to this molecule [130].
Since one of themost importantmechanisms in establish-
ing gastrointestinal inflammatory conditions is the activation
of different populations of T cells, the balance among effectors
and regulatory populations is crucial for driving the immune
response in GALT [131]. In this way, costimulatory signaling
of T cell activation has been investigated as a potential target
to block unwanted and deleterious inflammatory response.
One of these targets is the CTLA-4 molecule, expressed on
the surface of T cells, which selectively competes with CD28
molecule for binding to CD80 and CD86 molecules present
onAPCs. Besides that, it was recently demonstrated that both
T regulatory and T conventional cells exert a suppressive
function on the externalization of CTLA-4 protein [132].
Thus, new clinical approaches have used the biological
molecule abatacept, a fusion protein composed of the Fc
portion of IgG together with the CTLA4 molecule (CTLA4-
Ig), to treat different inflammatory disorders such as psoriatic
arthritis, type 1 diabetes, multiple sclerosis, and systemic
lupus erythematosus. However, a phase III trial in moderate-
to-severe CD and UC showed no therapeutic benefits with
the use of the abatacept, indicating that blocking the T cell
activation possibly compromises the activation of important
regulatory T cells subsets in IBD patients [133].
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3.2.3. Biological Drug Dosage. Nowadays, five biologic agents
are approved by FDA for the treatment of IBD: adali-
mumab, infliximab, golimumab, certolizumab pegol, and
vedolizumab. In order to reach an effective disease remission
of IBD patients, IFX standard dosage for UC and CD is
usually 5mg/kg by intravenous infusion at weeks 0, 2, and 6,
followed by a maintenance regimen every 8 weeks. However,
some data shows that the dosage of 10mg/kg seems to
maintain the remission for a longer period [134–137]. On the
other hand, ADA has shown to be effective to UC and CD by
the subcutaneous administration with an initial dose of 160
milligrams, a second dose two weeks later of 80mg, and a
maintenance dose of 40mg every other week, although it has
also been shown that there is a dose-dependent effectiveness
related to this drug [138–140].
In patients with moderate to severe CD, subcutaneous
administration of certolizumab pegol on subcutaneous doses
of 400mg once every 4 weeks was effective as induction
and maintenance therapy. In case of lack of response, it
should be given every 2 weeks [141]. The recommended
golimumab initial regimen for the treatment of UC is a
200mg subcutaneous dose at week 0 followed by 100mg at
week 2. The maintenance therapy is 100mg every 4 weeks
[67]. Vedolizumab was recently approved by FDA for the
treatment of adults withmoderately to severely activeUC and
CD. Dose regimen is 300mg infused intravenously at 0, 2,
and 6 weeks and the maintenance therapy at every 8 weeks
thereafter [74].
Despite the fact that there are no suficient comparative
trial data available between infliximab, adalimumab, and
certolizumab pegol, they are considered as having compa-
rable efficacy, especially when the maintenance of remission
is taking into consideration [68, 137]. An advantage of
ADA, golimumab, and certolizumab in comparison with
IFX and vedolizumab is that they can be administered by
a subcutaneous injection. It is important to mention that
patient’s history, drug regimen, and drug efficacy create a
singular scenario that should be taken into account before
choosing the appropriate therapy.
3.2.4. Biosimilars. Additionally, it is important to mention
that infliximab’s patent has already expired inmany countries
(e.g., Brazil, Argentina, Canada, South Korea, and some East-
ern Europe countries) and is about to in USA and inWestern
Europe countries, opening the opportunities for biosimilar
drugs to reach the market. Nowadays, IFX-biosimilars are
already used in some countries for the treatment of IBD and
present a significant reduction in costs.
Biosimilars present the same amino acid sequence and a
highly similar glycosylation pattern when compared with the
original product. Accordingly, biosimilars represent a future
tendency and a promising new option for IBD patients with
the main advantage of being less expensive, which may affect
the availability of the biological treatment for patients around
the world. However, concerns about the efficacy, safety, and
immunogenicity of biosimilars still exists [142, 143].
4. Final Considerations
Gastrointestinal immune disorders are most likely facilitated
by defects in the intestinal epithelial barrier and in the
mucosal immune system, resulting in an active inflammation
and tissue destruction.Themucosal immune system is essen-
tial for the establishment and controlling of the intestinal
inflammation and injury, with cytokines playing a central
role in modulating IBD. Therefore, using specific inhibitors
or blockers targeting cytokines and chemokines may be a
strategic move for treating IBD. Essentially, approved biolog-
ical molecules for commercial use act as specific inhibitors
of inflammatory cytokines related to autoimmune diseases.
Among approved TNF blockers, IFX and ADA are the
most commonly used biological drugs for the treatment of
IBD. Despite the fact that half of the patients treated with
these biological molecules have shown clinical remission and
its clinical benefits seemed to outweigh the risks involved,
there is a growing concern regarding the development of
immunogenicity against the biologics, since some patients
may develop anti-drug antibodies.
Albeitmany studies are still ongoingwith the goal of using
biological therapy, the effective cost of its production is very
elevated in comparison with other drugs, which might make
this a hard to implement treatment. Furthermore, treatment
with biologicals must be defined carefully, since several drugs
need further preclinical and clinical studies prior for their
use to be considered as a first option treatment. In this sense,
more controlled clinical trials are currently being conducted,
exploring the safety and efficacy of old and new biologic
agents. Regardless, the most recently engineered biological
drugs will certainly open a fresh and exciting perspective on
the development and improvement of therapies for IBD.
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